Literature DB >> 29770763

A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma.

Jie Peng1, Jing Zhang2, Qifan Zhang3, Yikai Xu2, Jie Zhou3, Li Liu1.   

Abstract

PURPOSE: We aimed to develop and validate a radiomics nomogram for preoperative prediction of microvascular invasion (MVI) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
METHODS: A total of 304 eligible patients with HCC were randomly divided into training (n=184) and independent validation (n=120) cohorts. Portal venous and arterial phase computed tomography data of the HCCs were collected to extract radiomic features. Using the least absolute shrinkage and selection operator algorithm, the training set was processed to reduce data dimensions, feature selection, and construction of a radiomics signature. Then, a prediction model including the radiomics signature, radiologic features, and alpha-fetoprotein (AFP) level, as presented in a radiomics nomogram, was developed using multivariable logistic regression analysis. The radiomics nomogram was analyzed based on its discrimination ability, calibration, and clinical usefulness. Internal cohort data were validated using the radiomics nomogram.
RESULTS: The radiomics signature was significantly associated with MVI status (P < 0.001, both cohorts). Predictors, including the radiomics signature, nonsmooth tumor margin, hypoattenuating halos, internal arteries, and alpha-fetoprotein level were reserved in the individualized prediction nomogram. The model exhibited good calibration and discrimination in the training and validation cohorts (C-index [95% confidence interval]: 0.846 [0.787-0.905] and 0.844 [0.774-0.915], respectively). Its clinical usefulness was confirmed using a decision curve analysis.
CONCLUSION: The radiomics nomogram, as a noninvasive preoperative prediction method, shows a favorable predictive accuracy for MVI status in patients with HBV-related HCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29770763      PMCID: PMC5951199          DOI: 10.5152/dir.2018.17467

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  39 in total

Review 1.  Hepatitis B virus and hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

3.  Imaging features of small hepatocellular carcinomas with microvascular invasion on gadoxetic acid-enhanced MR imaging.

Authors:  Myeong-Jin Kim; Myungsu Lee; Jin-Young Choi; Young Nyun Park
Journal:  Eur J Radiol       Date:  2011-12-03       Impact factor: 3.528

4.  Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value.

Authors:  G L Grazi; G Ercolani; F Pierangeli; M Del Gaudio; M Cescon; A Cavallari; A Mazziotti
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

5.  Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.

Authors:  Patrick P McHugh; Jeffrey Gilbert; Santiago Vera; Alvaro Koch; Dinesh Ranjan; Roberto Gedaly
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

6.  A pre-operative clinical model to predict microvascular invasion and long-term outcome after resection of hepatocellular cancer: The Australian experience.

Authors:  S M Schlichtemeier; T C Pang; N E Williams; A J Gill; R C Smith; J S Samra; V W T Lam; M Hollands; A J Richardson; H C Pleass; S Nozawa; M Albania; T J Hugh
Journal:  Eur J Surg Oncol       Date:  2016-06-11       Impact factor: 4.424

Review 7.  Multiple interactive factors in hepatocarcinogenesis.

Authors:  Jin Ding; Hongyang Wang
Journal:  Cancer Lett       Date:  2013-12-25       Impact factor: 8.679

8.  A Deep Learning-Based Radiomics Model for Prediction of Survival in Glioblastoma Multiforme.

Authors:  Jiangwei Lao; Yinsheng Chen; Zhi-Cheng Li; Qihua Li; Ji Zhang; Jing Liu; Guangtao Zhai
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

9.  Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers.

Authors:  Andrew J Vickers; Angel M Cronin; Elena B Elkin; Mithat Gonen
Journal:  BMC Med Inform Decis Mak       Date:  2008-11-26       Impact factor: 2.796

10.  Radiomics: Images Are More than Pictures, They Are Data.

Authors:  Robert J Gillies; Paul E Kinahan; Hedvig Hricak
Journal:  Radiology       Date:  2015-11-18       Impact factor: 11.105

View more
  64 in total

1.  An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study.

Authors:  Xiu-Ping Zhang; Kang Wang; Xu-Biao Wei; Le-Qun Li; Hui-Chuan Sun; Tian-Fu Wen; Zong-Tao Chai; Zhen-Hua Chen; Jie Shi; Wei-Xing Guo; Dong Xie; Wen-Ming Cong; Meng-Chao Wu; Wan Yee Lau; Shu-Qun Cheng
Journal:  Oncologist       Date:  2019-05-28

Review 2.  Artificial intelligence in assessment of hepatocellular carcinoma treatment response.

Authors:  Bradley Spieler; Carl Sabottke; Ahmed W Moawad; Ahmed M Gabr; Mustafa R Bashir; Richard Kinh Gian Do; Vahid Yaghmai; Radu Rozenberg; Marielia Gerena; Joseph Yacoub; Khaled M Elsayes
Journal:  Abdom Radiol (NY)       Date:  2021-03-31

Review 3.  Radiomics with artificial intelligence: a practical guide for beginners.

Authors:  Burak Koçak; Emine Şebnem Durmaz; Ece Ateş; Özgür Kılıçkesmez
Journal:  Diagn Interv Radiol       Date:  2019-11       Impact factor: 2.630

Review 4.  Radiomics of hepatocellular carcinoma.

Authors:  Sara Lewis; Stefanie Hectors; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2021-01

Review 5.  Radiomics: an Introductory Guide to What It May Foretell.

Authors:  Stephanie Nougaret; Hichem Tibermacine; Marion Tardieu; Evis Sala
Journal:  Curr Oncol Rep       Date:  2019-06-25       Impact factor: 5.075

6.  CT Image-Based Texture Analysis to Predict Microvascular Invasion in Primary Hepatocellular Carcinoma.

Authors:  Yueming Li; Xuru Xu; Shuping Weng; Chuan Yan; Jianwei Chen; Rongping Ye
Journal:  J Digit Imaging       Date:  2020-09-23       Impact factor: 4.056

7.  MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma.

Authors:  Stefanie J Hectors; Sara Lewis; Cecilia Besa; Michael J King; Daniela Said; Juan Putra; Stephen Ward; Takaaki Higashi; Swan Thung; Shen Yao; Ilaria Laface; Myron Schwartz; Sacha Gnjatic; Miriam Merad; Yujin Hoshida; Bachir Taouli
Journal:  Eur Radiol       Date:  2020-02-21       Impact factor: 5.315

8.  Texture analysis on gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: A prospective study.

Authors:  Zheng Ye; Hanyu Jiang; Jie Chen; Xijiao Liu; Yi Wei; Chunchao Xia; Ting Duan; Likun Cao; Zhen Zhang; Bin Song
Journal:  Chin J Cancer Res       Date:  2019-10       Impact factor: 5.087

9.  Considerable effects of imaging sequences, feature extraction, feature selection, and classifiers on radiomics-based prediction of microvascular invasion in hepatocellular carcinoma using magnetic resonance imaging.

Authors:  Houjiao Dai; Minhua Lu; Bingsheng Huang; Mimi Tang; Tiantian Pang; Bing Liao; Huasong Cai; Mengqi Huang; Yongjin Zhou; Xin Chen; Huijun Ding; Shi-Ting Feng
Journal:  Quant Imaging Med Surg       Date:  2021-05

10.  A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma.

Authors:  Rui Zhang; Lei Xu; Xue Wen; Jiahui Zhang; Pengfei Yang; Lixia Zhang; Xing Xue; Xiaoli Wang; Qiang Huang; Chuangen Guo; Yanjun Shi; Tianye Niu; Feng Chen
Journal:  Quant Imaging Med Surg       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.